Skip to main content
. 2018 Jun 1;9(42):26701–26710. doi: 10.18632/oncotarget.25468

Figure 1. Prognostic value of TOP2A overexpression in each breast cancer subtype.

Figure 1

Relapse-free survival of (A) all (n = 643), (B) luminal A (n = 108), (C) luminal B (n = 315), (D) HER2 (n = 135), and (E) TNBC (n = 85) subtypes stratified by TOP2A overexpression. P value was evaluated using the log-rank test. Abbreviations: HER2: human epidermal growth factor receptor 2; TNBC: triple negative breast cancer.